Effects of erythropoietin (epoetin-alfa) on infarct size and left ventricular remodeling in survivors of large myocardial infarctions
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms REVEAL
- 18 May 2012 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
- 18 May 2012 Actual initiation date changed from 1 Sep 2006 to 1 Sep 2005, lead trial investigator added (Lakatta EG) as reported by ClinicalTrials.gov.
- 18 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.